TABLE 2.
Human FcRn binding to various motavizumab IgGs and hFcRn transgenic mouse PK data
| Motavizumab construct | pH 6 Hu FcRn KDa | pH 7.4 Hu FcRn KDa | Clearance | β-Phase t½ | AUCinf |
|---|---|---|---|---|---|
| nm | nm | ml/day/kg | days | μg·day/kg | |
| Wild type | 2140 | >10,000 | 60.1 | 0.73 | 42 |
| YTE | 314 | >10,000 | 23.3 | 3.28 | 108 |
| N3E-YTE | 3 | 25 | 373.0 | 0.78 | 7 |
| N3-YTE | 13 | 383 | 61.9 | 0.54 | 40 |
| N3E | 41 | 860 | 33.3 | 2.16 | 75 |
| Y31-YTE | 84 | 1160 | 23.8 | 3.65 | 105 |
| Y3-YTE | 53 | 2680 | 26.4 | 2.07 | 95 |
| Y12-YTE | 86 | 5040 | 26.4 | 2.75 | 94 |
| Y12 | 254 | >10,000 | 32.3 | 2.44 | 71 |
| Y31 | 491 | >10,000 | 37.5 | 2.99 | 67 |
a Steady-state affinity measurements carried out by ProteOn as described under “Experimental Procedures.” Values in italic type were determined via kinetic model (Langmuir with mass transfer).